CA3176994A1 - Treatments of inflammatory bowel disease - Google Patents
Treatments of inflammatory bowel disease Download PDFInfo
- Publication number
- CA3176994A1 CA3176994A1 CA3176994A CA3176994A CA3176994A1 CA 3176994 A1 CA3176994 A1 CA 3176994A1 CA 3176994 A CA3176994 A CA 3176994A CA 3176994 A CA3176994 A CA 3176994A CA 3176994 A1 CA3176994 A1 CA 3176994A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- pharmaceutical composition
- hydrogen
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2006390.5 | 2020-04-30 | ||
| GBGB2006390.5A GB202006390D0 (en) | 2020-04-30 | 2020-04-30 | Novel treatments |
| PCT/EP2021/061462 WO2021219879A1 (en) | 2020-04-30 | 2021-04-30 | Treatments of inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3176994A1 true CA3176994A1 (en) | 2021-11-04 |
Family
ID=71080611
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3176994A Pending CA3176994A1 (en) | 2020-04-30 | 2021-04-30 | Treatments of inflammatory bowel disease |
| CA3177000A Pending CA3177000A1 (en) | 2020-04-30 | 2021-04-30 | Novel compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3177000A Pending CA3177000A1 (en) | 2020-04-30 | 2021-04-30 | Novel compounds |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20230167064A1 (OSRAM) |
| EP (2) | EP4142725A1 (OSRAM) |
| JP (2) | JP7702427B2 (OSRAM) |
| KR (2) | KR20230018386A (OSRAM) |
| CN (2) | CN115768429B (OSRAM) |
| AU (2) | AU2021266154A1 (OSRAM) |
| CA (2) | CA3176994A1 (OSRAM) |
| GB (2) | GB202006390D0 (OSRAM) |
| WO (2) | WO2021219879A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202006390D0 (en) * | 2020-04-30 | 2020-06-17 | Aqilion Ab | Novel treatments |
| AU2021275994A1 (en) * | 2020-05-21 | 2022-12-22 | Stemsynergy Therapeutics, Inc. | Notch inhibitors and uses thereof |
| CN115120727B (zh) * | 2022-06-16 | 2024-02-23 | 甘肃农业大学 | S100a9抑制剂在制备防治c型产气荚膜梭菌感染性腹泻药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
| EP2061440A2 (en) * | 2007-04-04 | 2009-05-27 | Sigmoid Pharma Limited | A pharmaceutical composition of tacrolimus |
| ES2564931T3 (es) | 2009-07-30 | 2016-03-30 | Teva Pharmaceutical Industries Ltd. | Tratamiento de enfermedad de Crohn con laquinimod |
| EA201390074A1 (ru) * | 2010-07-09 | 2013-06-28 | Тева Фармасьютикал Индастриз Лтд. | 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения |
| CN104610144A (zh) * | 2010-07-09 | 2015-05-13 | 泰华制药工业有限公司 | 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途 |
| KR20130065728A (ko) | 2010-10-14 | 2013-06-19 | 임뮤나르 에이비 | Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드 |
| US9200046B2 (en) * | 2011-06-29 | 2015-12-01 | Cornell University | Reporter system for high throughput screening of compounds and uses thereof |
| GB202006390D0 (en) * | 2020-04-30 | 2020-06-17 | Aqilion Ab | Novel treatments |
-
2020
- 2020-04-30 GB GBGB2006390.5A patent/GB202006390D0/en not_active Ceased
-
2021
- 2021-04-30 AU AU2021266154A patent/AU2021266154A1/en active Pending
- 2021-04-30 AU AU2021262514A patent/AU2021262514A1/en active Pending
- 2021-04-30 GB GB2207709.3A patent/GB2605894B/en active Active
- 2021-04-30 CA CA3176994A patent/CA3176994A1/en active Pending
- 2021-04-30 WO PCT/EP2021/061462 patent/WO2021219879A1/en not_active Ceased
- 2021-04-30 US US17/922,043 patent/US20230167064A1/en active Pending
- 2021-04-30 CA CA3177000A patent/CA3177000A1/en active Pending
- 2021-04-30 EP EP21723216.4A patent/EP4142725A1/en active Pending
- 2021-04-30 KR KR1020227041920A patent/KR20230018386A/ko active Pending
- 2021-04-30 JP JP2022566660A patent/JP7702427B2/ja active Active
- 2021-04-30 CN CN202180044567.7A patent/CN115768429B/zh active Active
- 2021-04-30 KR KR1020227041908A patent/KR20230024892A/ko active Pending
- 2021-04-30 JP JP2022566661A patent/JP2023524519A/ja active Pending
- 2021-04-30 US US17/922,072 patent/US20230202982A1/en active Pending
- 2021-04-30 EP EP21723215.6A patent/EP4142724A1/en active Pending
- 2021-04-30 WO PCT/EP2021/061464 patent/WO2021219881A1/en not_active Ceased
- 2021-04-30 CN CN202180043624.XA patent/CN115916200A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230024892A (ko) | 2023-02-21 |
| GB2605894A (en) | 2022-10-19 |
| GB202207709D0 (en) | 2022-07-06 |
| JP2023524519A (ja) | 2023-06-12 |
| EP4142724A1 (en) | 2023-03-08 |
| AU2021262514A1 (en) | 2023-01-05 |
| AU2021266154A1 (en) | 2023-01-05 |
| US20230167064A1 (en) | 2023-06-01 |
| GB202006390D0 (en) | 2020-06-17 |
| CN115916200A (zh) | 2023-04-04 |
| KR20230018386A (ko) | 2023-02-07 |
| WO2021219881A1 (en) | 2021-11-04 |
| JP7702427B2 (ja) | 2025-07-03 |
| CA3177000A1 (en) | 2021-11-04 |
| US20230202982A1 (en) | 2023-06-29 |
| CN115768429B (zh) | 2024-02-09 |
| CN115768429A (zh) | 2023-03-07 |
| GB2605894B (en) | 2023-06-14 |
| JP2023524518A (ja) | 2023-06-12 |
| EP4142725A1 (en) | 2023-03-08 |
| WO2021219879A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU742941B2 (en) | Sustained release tablet formulation to treat parkinson disease | |
| EP0701819B1 (en) | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | |
| TWI305148B (OSRAM) | ||
| JP7369769B2 (ja) | アミノピリミジン誘導体又はその塩を含む経口投与用医薬組成物 | |
| US20230167064A1 (en) | Treatments of inflammatory bowel disease | |
| IL197235A (en) | Medical and product preparations containing ingredients that have pde5 inhibitor properties and their use in the manufacture of drugs | |
| CN114907353A (zh) | 一种前药化合物及其制备方法和用途 | |
| NZ565522A (en) | Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of Huntington's disease | |
| EA014739B1 (ru) | Композиция тразодона для введения один раз в день | |
| CN111655693A (zh) | 抑制瞬时型感受器电位a1离子通道 | |
| CA3212009C (en) | Pharmaceutical compositions comprising a functional antagonist for S1PR1 and S1PR4 for the prevention or treatment of an inflammatory bowel disease | |
| JPH0526782B2 (OSRAM) | ||
| CN117362200B (zh) | 苯甲胺类化合物及其合成方法与应用 | |
| JP2024507213A (ja) | Ｎ－（（ｒ）－２，３－ジヒドロキシプロポキシ）－３，４－ジフルオロ－２－（２－フルオロ－４－ヨード－フェニルアミノ）－ベンズアミドの分散性製剤及びその使用 | |
| ZA200107244B (en) | Benzamide derivatives and drugs containing the same | |
| EP1973887B1 (en) | Aza heterocyclics for the treatment of malaria or aids | |
| EP0900796B1 (en) | Preventives and remedies for ischemic intestinal lesion and ileus | |
| HU192050B (en) | Process for production of medical preparative containing co-dergocrin and one piridin-dicarbonic acid diesthertype calcium-antagonist | |
| CN101400352B (zh) | 用于治疗和预防疾病的组合物和方法 | |
| WO2017201364A1 (en) | Method for improving or enhancing cognition | |
| CN1728998A (zh) | 杂环胺类化合物作为神经保护剂的用途 | |
| KR20010013274A (ko) | 2-(4-(4-(4,5-디클로로-2-메틸이미다졸-1-일)부틸)-1-피페라지닐)-5-플루오로피리미딘, 이것의 제조 방법 및 이것의치료적 용도 | |
| HK1133597B (en) | Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor | |
| HK1082518A (en) | Use of heterocyclic amine-type compounds as neuroprotective agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250326 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250326 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250326 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250430 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250430 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250620 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250620 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250714 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250714 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250714 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250714 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260309 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260331 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260415 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260415 |